Atsushi Fujiwara*, Masamichi Yoshida*, Hajime Fujimoto†, Hiroki Nakahara†, Kentaro Ito‡, Kota Nishihama§, Taro Yasuma§, Osamu Hataji‡, Osamu Taguchi¶, Corina N. D’Alessandro-Gabazza§, Esteban C. Gabazza§, Tetsu Kobayashi†
Oncology Research, Vol.26, No.7, pp. 1031-1036, 2018, DOI:10.3727/096504018X15151523767752
Abstract Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by
epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there
were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy of NSCLC in Japan.
Osimertinib can be indicated only against T790M+
lung cancer as a second-line therapy. However, whether
gefitinib, erlotinib, or afatinib is most appropriate as a first-line therapy is still a controversial issue. The aim of
this study was to compare the effectiveness of gefitinib, erlotinib, and afatinib. We retrospectively reviewed… More >
Login
Register
